bioMérieux S.A
bioMérieux S.A. develops, manufactures, and markets in vitro diagnostic solutions for infectious diseases in France, Europe, Africa, the Middle East, North and South America, the Asia Pacific, and internationally. It operates through Clinical Applications and Industrial Applications segments. The company offers CHROMID RANGE, a chromogen culture media; air, surface, and water monitoring systems; … Read more
bioMérieux S.A - Asset Resilience Ratio
bioMérieux S.A (BMXMF) has an Asset Resilience Ratio of -0.38% as of December 2022. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2012–2023)
This chart shows how bioMérieux S.A's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down bioMérieux S.A's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $-19.80 Million | -0.38% |
| Total Liquid Assets | $-19.80 Million | -0.38% |
Asset Resilience Insights
- Limited Liquidity: bioMérieux S.A maintains only -0.38% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
bioMérieux S.A Industry Peers by Asset Resilience Ratio
Compare bioMérieux S.A's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ADCNF
OTCGREY:ADCNF |
Diagnostics & Research | 1.12% |
|
Berry Genomics Co Ltd
SHE:000710 |
Diagnostics & Research | 0.45% |
|
NSN Co. Ltd
KQ:031860 |
Diagnostics & Research | 1.72% |
|
JOONGANG DNM Co.Ltd
KQ:051980 |
Diagnostics & Research | 27.26% |
|
GeneMatrix Inc
KQ:109820 |
Diagnostics & Research | 41.52% |
|
Genoray Co. Ltd
KQ:122310 |
Diagnostics & Research | 0.03% |
|
Green Cross Lab Cell Corporation
KQ:144510 |
Diagnostics & Research | 0.18% |
|
Optipharm.CO.LTD
KQ:153710 |
Diagnostics & Research | 20.73% |
Annual Asset Resilience Ratio for bioMérieux S.A (2012–2023)
The table below shows the annual Asset Resilience Ratio data for bioMérieux S.A.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 0.27% | $14.20 Million | $5.26 Billion | +0.65pp |
| 2022-12-31 | -0.38% | $-19.80 Million | $5.19 Billion | +0.21pp |
| 2021-12-31 | -0.60% | $-27.50 Million | $4.62 Billion | -0.32pp |
| 2020-12-31 | -0.27% | $-10.70 Million | $3.93 Billion | +0.00pp |
| 2019-12-31 | -0.27% | $-10.40 Million | $3.78 Billion | +0.11pp |
| 2018-12-31 | -0.38% | $-13.00 Million | $3.39 Billion | -3.39pp |
| 2017-12-31 | 3.00% | $89.80 Million | $2.99 Billion | +3.21pp |
| 2016-12-31 | -0.20% | $-6.20 Million | $3.03 Billion | +0.03pp |
| 2015-12-31 | -0.23% | $-6.40 Million | $2.77 Billion | +0.03pp |
| 2014-12-31 | -0.26% | $-6.70 Million | $2.58 Billion | +0.05pp |
| 2013-12-31 | -0.31% | $-6.90 Million | $2.20 Billion | +0.06pp |
| 2012-12-31 | -0.37% | $-6.80 Million | $1.83 Billion | -- |